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High frequency of antibiotic resistance among
Gram-negative isolates in intensive care units at
10 Swedish hospitals
Hakan Hanberger1) Lennart E. Nilsson 2 and the Swedish Study Groupt
Departments of lInfectious Diseases and 2Clinical Microbiology, University Hospital, Linkoping,
Sweden
Objective: To investigate the resistance rates among Gram-negative isolates in Swedish intensive care units (lCUs).
Methods: During 1994-95, members of the Swedish Study Group collected, on clinical indication, 502 consecutive
initial isolates of Gram-negative bacteria from patients admitted to ICUs at 10 Swedish hospitals and performed minimal
inhibitory concentration (MIC) determinations with the Etest. Breakpoints were defined according to the criteria of the
Swedish Reference Group for Antibiotics (SRGAl.
Results: The distribution of bacterial species was: Escherichia coli> Klebsiella spp. > Enterobacterspp. > Pseudomonas
aeruginosa > Haemophilus spp. > Proteus spp. > Stenotrophomonas maltophilia > Citrobacter spp. > Acinetobacter>
Pseudomonas spp. > Morganella morganii> Serratia spp. Together these constituted 97% of all isolates. The frequencies
of resistance for all the initial Gram-negative isolates were: ceftazidime 6.8%, cefotaxime 14.9%, ceftriaxone 18.5%,
cefuroxime 44.1%, ciprofloxacin 4.2%, co-trimoxazole 17.8%, gentamicin 5.8%, imipenem 8.6%, piperacillin 20.2%,
piperacillin/tazobactam 12.9% and tobramycin 5.8%.
Conclusions: Among Gram-negative isolates in Swedish ICUs, a very high frequency of resistance was seen to
cefuroxime, and rather high frequencies of resistance to cefotaxime, ceftriaxone, piperacillin and piperacillinl
tazobactam. These drugs cannot be recommended for further use as empirical monotherapy for severe ICU-acquired
Gram-negative infections in ICUs in Sweden.
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INTRODUCTION
In a recent European prevalence study it was shown that
20.6% of intensive care unit (ICU) patients had an
ICU-acquired infection [1]. The nosocomial infection
rates among ICU patients are 5-10 times higher than
among general ward patients [2,3] and most epidemics
originate in ICUs [3-6]. ICU-acquired infections are
often associated with microbiological isolates of
resistant organisms [4,7]. Selective pressure exerted by
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heavy antibiotic use, as in ICUs, is the driving force
behind the emergence of antibiotic resistance; even-
tually, bacteria develop resistance to practically all
antibiotics [8]. Surveillance of antibiotic resistance is
especially important in ICUs, since infection rates are
much higher there than in other hospital wards [2,3].
The best current strategy for preventing ICU infections
and the spread of antibiotic-resistant bacteria involves
emphasizing handwashing between patient contacts,
keeping the use of invasive devices to a minimum, and
the restriction of antibiotic use [4,9,10]. A lower
t Participants in the Swedish Study Group were:
J.-E. Brorson (Uddevallal, B. Claesson (Sk6vdel, H. Fritz
and T. Ripa (Halmstad), H. J6rbeck (Danderyd), A. Kamel!
(Stockholm), P. Larsson (G6teborg), A. L6vestad (Eskilstuna),
A.-S. Malmborg (Stockholm), J. Rydberg (Helsingborg),
M. Rylander (Stockholm).
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incidence of antibiotic resistance among Gram-negative
blood isolates has been reported in Sweden as com-
pared to the incidence in southern Europe [11-15].
However, in a recent survey ofbacterial resistance of all
isolates collected from 1993 to 1994 in four ICUs at a
Swedish university hospital, 13-lactam resistance among
Enterobacter spp. and Enterococcus spp. showed an increase
[16]. A simultaneous survey of all blood isolates from
the four hospitals in the same county revealed the same
emergence of resistance, but at a lower rate compared
to those in the ICUs [16]. The aim of this study was to
investigate the prevalence ofantibiotic resistance among
100 consecutively collected Gram-negative bacteria in
10 different ICUs in Sweden.
Table 2 Sources of the isolates
Respiratory aspirate!drain!
lavage!pleural!sputum
Urine
Tracheal
Abdominal wound!drain!bile!
peritoneum
Ear!nose
Blood
Skin and soft tissue
Others
Total
Isolates (%)
149 29.7
81 16.1
66 13.1
63 12.5
45 9.0
33 6.6
21 4.2
44 8.8
502 100
MATERIALS AND METHODS
Study design and culture collection
A Swedish multicenter susceptibility testing study was
performed on isolates collected from August 1994
to June 1995 from patients admitted to ICUs in 10
different hospitals. The cultures were performed con-
secutively on clinical indications. The mean collection
time was 7 months (range 3.5-8.5 months). Four
hospitals were tertiary university hospitals and six were
primary county hospitals. Seven hundred and fifty-
nine consecutive Gram-negative bacterial isolates were
collected from 347 patients admitted to the ICUs. Of
these isolates, 502 were initial isolates (Table 1) and 257
were repeat isolates of the same species from the same
patient. The repeat isolates were not included in the
analysis of data except for a comparison between
the 502 (initial) isolates and the 759 (initial and repeat)
isolates. The sources of the isolates are shown in
Table 2.
Susceptibility testing
Minimal inhibitory concentration (MIC) was deter-
mined using Etest (AB BIODISK, Solna, Sweden)
[17-19]. Resistant strains were defined according to the
MIC breakpoints of the Swedish Reference Group of
Antibiotics (SRGA) [20]. These SRGA breakpoints for
susceptible/resistant isolates are shown in Table 3,
together with corresponding breakpoints from the
National Committee for Clinical Laboratory Standards
(NCCLS) [21].
An attempt to detect extended-spectrum 13-lacta-
mases (ES13L) of Escherichia coli and Klebsiella spp.
was performed by using two Etest strips: one with
ceftazidime alone and one with ceftazidime in com-
bination with clavulanic acid (AB BIODISK, SoIna,
Sweden). Isolates with a reduction of ceftazidime MIC
by 2:3 two-fold dilutions in the presence of clavulanic
acid were considered ES13L-positive [22].
Table 3 MIC breakpoints (mg/L) for susceptible and
resistant organisms according to the Swedish Reference
Table 1 Distribution of genera and species among Group of Antibiotics (SRGA) [20] and the National
consecutively collected initial isolates of Gram-negative Committee for Clinical Laboratory Standards (NCCLS) [21]
bacilli in 10 lCUs in Sweden
SRGA NCeLS
Isolates (%) Patients Susceptible Resistant Susceptible Resistant
Escherichia coli 128 (25.5) 128 Imipenem ,;;4 ;,,16 ,;;4 ;,,16
Klebsiella spp. 70 (13.8) 68 Ceftazidime ,;;4 ;,,16 ,;;8 ;,,32
Enterobacter spp. 68 (13.4) 62 Cefotaxime ,;;4 ;,,16 ,;;8 ;,,64
Pseudomonas aeruginosa 59 (11.8) 59 Ceftriaxone ,;;4 ;,,16 ,;;8 ;,,64
Haemophilus spp. 39 (7.7) 38 Cefuroxime ,;;4 ;,,16 ,;;8 ;,,32
Proteus spp. 31 (6.2) 31 Piperacillin ,;;16 ;,,32 ,;;16 ;,,128
Stenotrophomonas maltophilia 28 (5.5) 28 Piperacillin +
Citrobacter spp. 21 (4.2) 20 P. aeruginosa ,;;16 ;,,32 ,;;64 ;,,128
Acinetobaeter spp. 16 (3.2) 16 Piperacillin!
Pseudomonas spp. 12 (2.4) 12
tazobactam ,;;16 ;,,32 ,;;16!4 ;,,128/4
Serratia spp. 9 (1.8) 9 Gentamicin ,;;4 ;,,8 ,;;4 ;,,16
Morganella morganii 7 (1.4) 7 Tobramycin ,;;4 ;,,8 ,;;4 ;,,16
Others 14 (2.8) Co-trimoxazole ,;;32 ;,,64 ,;;2138 ;,,4/76
Total 502 (100) Ciprofloxacin ,;;1 ;,,8 ,;;1 ;,,4
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All Gram-negative isolates
KlebsIella species
Escherichia coli
Enterobacter species
Pseudomonas aeruglnosa Stenotrophomonas ma/tophll/a
Figure 1 The resistance rates among all initial Gram-negative isolates and all initial + repeat isolates, and the resistance rates
for initial isolates of Escherichia coli, Klebsiella spp., Enterobacter spp., Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
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Figure 2 MlC distributions of initial isolates for ceftazidime, cefuroxime, ciprofloxacin, imipencm and tobramycin in
Escherichia coli, Klebsiella spp. and Enterobacter spp., for ceftazidime, ciprofloxacin, irnipenem and tobramycin In P. aeruginosa,
and for ceftazidime, ciprofloxacin, co-trimoxazole and tobramycin in S. maltophilia.
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Enterobacter species Pseudomonas aeruglnosa
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Figure 2 continued
Hanberger et al: Antibiotic resistance among Gram-negative bacteria in ICUs 213
12
10
.! 8
:g
1; 6
~
~ 4
Z
Stenotrophomonas maltophilia RESULTS
Distribution of bacterial species
The distribution of bacterial species 1S shown in
Table 1.
Sources of the isolates
The sources of the isolates are shown in Table 2.
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Susceptibility
The resistance rates among all initial Gram-negative
isolates and all initial + repeat isolates and the resistance
rates for Escherichia coli, Klebsiella spp., Enterobacter spp.,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia
to the antibiotics are shown in Figure 1.
MIC-distributions
The MIC distributions for E. coli, Klebsiella spp., Entero-
bacter spp, P aeruginosa and S. maltophilia to selected
antibiotics are shown in Figure 2.
University hospitallCUs versus county hospitallCUs
Four of the participating hospitals were tertiary univer-
sity hospitals (248 initial isolates) and six were primary
county hospitals (254 initial isolates). The percentage
resistance rates in the university hospital ICUs/
county hospital ICUs were: ceftazidime 7.7%/5.9'%,
cefotaxime 14.1 %/15.7%, ceftriaxone 21.8%/15.0%,
cefuroxime 45.3%/42.9%, ciproBoxacin 4.4%/3.9%,
co-trimoxazole 13.8%/21.7%, gentamicin 8.1 %/3.6%"
llmpenem 8.9%/8.3%, piperacillin 25.8%/14.6%"
piperacillin/tazobactam 15.3%/10.6% and tobramycin
8.5%/3.1%.
Extended-spectrum 13-lactamases (ESl3lsl
One of a total of 128 E. coli isolates and four of a total
of70 Klebsiella spp. isolates had an Etest® MIC ratio for
cefrazidime and ceftazidime/cJavulanic acid indicating
the presence of E/3BLs.
~O.25 0.5
Figure 2 continued
DISCUSSION
This study showed that of all the consecutively collected
initial Gram-negative isolates in Swedish ICUs, 44.1 %
were resistant to cefuroxime, 14.9% to cefotaxime,
18.5% to ceftriaxone, 17.8% to co-trimoxazole, 20.2%
to piperacillin and 12.9% to piperacilIin/tazobactam.
Such a high antibiotic resistance level among Gram-
negative isolates has not, to our knowledge, been
previously reported from Scandinavia. Resistance
surveillance studies in Sweden have earlier focused
mainly on blood isolates, and only low-level antibiotic
resistance has been reported in these studies [11-151.
However, a trend towards increasing resistance aIllong
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Enterobacter spp. and Enterococcus spp. to /3-lactam anti-
biotics could be seen in an investigation of antibiotic
resistance during 1993-94 in the ICUs of one Swedish
university hospital [16].
The breakpoints for susceptibility and resistance to
cefuroxime divide the main MIC populations ofE. coli,
Klebsiella spp. and E. cloacae into two parts when SRGA
breakpoints are used, but not when NCCLS break-
points are used (Figure 2, Table 3). To circumvent this
problem, species-related breakpoints may have to be
defined. In contrast to cefuroxime the SRGA and
NCCLS breakpoints for susceptibility and resistance to
cefotaxime, ceftazidime and ceftriaxone of E. coli and
Klebsiella spp. are several dilution steps from the main
MIC population, which makes it hard to detect bacteria
with acquired low-level resistance. This also supports a
change to species-related breakpoints.
The resistance rates for all Gram-negative bacteria
to ceftazidime, ciprofloxacin, gentamicin, imipenem
and tobramycin were 6.8%, 4.2%, 5.8%, 8.6% and
5.8%, respectively (Figure 1). These figures indicate
that, ofthe tested antibiotics, ceftazidime, ciprofloxacin,
gentamicin, imipenem and tobramycin are the best
empirical treatments for Gram-negative infections in
ICUs in Sweden. However, these drugs may select
multiresistant Enterococcus faecium, which is an increasing
problem in Swedish ICUs [16]. This is in agreement
with unpublished results from seven of 10 Swedish
ICUs participating in this study showing that 24%
of Enterococcus spp. had decreased susceptibility to
ampicillin.
Enterobacter was the third most frequent Gram-
negative genus in this study (Table 1). The resistance
rates among Enterobacter spp. to ceftazidime, cefotaxime,
ceftriaxone, cefuroxime, piperacillin and piperacillin/
tazobactam were 26.5%, 26.5%, 26.5%, 61.8%, 26.5%
and 26.5%, respectively, whereas no Enterobacter spp.
were resistant to imipenem, gentamicin or cipro-
floxacin (Figures 1 and 2). This resistance is probably
due to selection of Enterobacter spp. producing high
levels ofchromosomal class I /3-lactamases, which cause
resistance to all second- and third-generation cephalo-
sporins [23-26]. Previous administration of third-
generation cephalosporins is more likely to be associated
with multiresistant blood isolates of Enterobacter spp.,
causing a higher mortality rate, than administration of
other antibiotics, as shown in a study by Chow et al
[27]. The resistance rates for P. aeruginosa were 1.7% for
ceftazidime, 6.8% for ciprofloxacin, 6.8% for genta-
micin, 8.5% for piperacillin, 8.5% for piperacillin/
tazobactam, 13.8% for imipenem and 5.1% for
tobramycin (Figure 1). The /3-lactamase inhibitor
tazobactam in piperacillin/tazobactam is not stable to
the class 1 /3-lactamases produced by P. aeruginosa or
Enterobacter spp., which is confirmed by the same level
of resistance for the combination with tazobactam
compared to piperacillin alone, as shown in this study
(Figure 1).
The frequencies of resistance among all Gram-
negative bacteria were higher for most antibiotics in the
university hospital ICUs compared with the county
hospital ICUs. This may be a result of more extensive
antibiotic use in the university hospital ICUs due to a
higher prevalence of severe cases causing longer ICU
stays.
No analysis was performed in the present study
to determine whether the isolates collected caused
infection or only reflected colonization of the critically
ill patient. However, only a small number of all isolates
could be considered opportunistic, and colonization
with multiresistant pathogens is very often a pre-
requisite for infection [28].
The multiple antibiotic-resistant S. maltophilia is of
major concern primarily in immunocompromised
cancer patients and transplant recipients [29]. Risk
analysis has shown that mechanically ventilated ICU
patients receiving antibiotics, especially carbapenems,
are at increased risk of colonization/infection with
S. maltophilia [29]. A more liberal indication for
isolation ofpatients colonized with S. maltophilia is now
appropriate, and a more judicious use of carbapenems
will decrease the selective pressure on multiresistant
S. maltophilia.
In conclusion, this study showed a very high
frequency of resistance among Gram-negative isolates
in Swedish ICUs to cefuroxime, and a rather high
frequency of resistance to cefotaxime, ceftriaxone,
piperacillin and piperacillin/tazobactam (Figure 1).
These drugs cannot be recommended for further use as
empirical monotherapy for severe ICU-acquired Gram-
negative infections in ICUs in Sweden. Furthermore,
these high frequencies of resistance among Gram-
negative isolates, not previously reported in Sweden,
pose a threat to patients in Swedish ICUs. To reduce
the spread of resistant bacterial isolates there is a need
for identification of reservoirs and isolation of patients
with resistant isolates and, ifpossible, the eradication of
these isolates by means ofjudicious antibiotic treatment.
Antibiotic resistance surveillance programs associated
with registration ofantibiotic consumption are necessary
to promote optimal use of antibiotics, especially in
rcus.
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